Clinical trial NCT03656536: A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
Official title: A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Unresectable Cholangiocarcinoma
Metastatic Cholangiocarcinoma
Keywords: Cholangiocarcinoma
fibroblast growth factor receptor inhibitor
FGFR
FGFR rearrangement
Lead sponsor: Incyte Corporation
Sponsor class: INDUSTRY
First posted: 2018-09-04
Enrollment: 167
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.


Eligibility criteria: Inclusion Criteria:

* Male and female participants at least 18 years of age at the time of signing the informed consent form (ICF).
* Histologically or cytologically confirmed cholangiocarcinoma that is previously untreated and considered unresectable and/or metastatic (Stage IV per the American Joint Committee on Cancer (AJCC) Cancer Staging Manual).
* Radiographically measurable or evaluable disease by CT or MRI per RECIST v1.1 criteria.
* Eastern Cooperative Oncology Group performance status 0 to 1.
* Documented FGFR2 rearrangement.
* Willingness to avoid pregnancy or fathering children.

Exclusion Criteria:

* Received prior anticancer systemic therapy for unresectable and/or metastatic disease (not including adjuvant/neo-adjuvant treatment completed at least 6 months prior to enrollment, and participants that have received treatment for locally advanced disease with trans-arterial chemoembolization or selective internal radiation therapy, if clear evidence of radiological progression is observed before enrollment, or enrolled as of Amendment 6 (or Amendment 5-JP2) and the participant received 1 cycle of gemcitabine plus cisplatin \[the start of study drug {Cycle 1 Day 1} must be at least 14 days and ≤ 4 weeks {28 days} from the last dose of gemcitabine plus cisplatin\]).
* Child-Pugh B and C.
* Toxicities related to prior therapy(ies) must be Common Terminology Criteria for Adverse Events (CTCAE) v5.0 ≤ Grade 1 at the time of screening.
* Concurrent anticancer therapy, other than the therapies being tested in this study.
* Participant is a candidate for potentially curative surgery.
* Current evidence of clinically significant corneal (including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, and keratoconjunctivitis) or retinal disorder (including but not limited to central serous retinopathy, macular/retinal degeneration, diabetic retinopathy, retinal detachment) as confirmed by ophthalmologic examination.
* Radiation therapy administered within 4 weeks of enrollment/randomization/first dose of study treatment.
* Known central nervous system (CNS) metastases or history of uncontrolled seizures.
* Known additional malignancy that is progressing or requires active treatment (exceptions: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy).
* Laboratory values at screening outside the protocol-defined range.
* History of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues (exception: commonly observed calcifications in soft tissues, such as the skin, kidney, tendons or vessels due to injury, disease, and aging, in the absence of systemic mineral imbalance).
* Significant gastrointestinal disorders that could interfere with absorption, metabolism, or excretion of pemigatinib.
* Clinically significant or uncontrolled cardiac disease.
* History or presence of an abnormal ECG, which, in the investigator's opinion, is clinically meaningful.
* Chronic or current active infectious disease requiring systemic antibiotics or antifungal or antiviral treatment within 2 weeks prior to enrollment (participants with asymptomatic chronic infections on prophylactic treatment are allowed). Note: HIV-positive participants are allowed if all of the following criteria are met: CD4+ count ≥ 300/µL, undetectable viral load, receiving antiretroviral therapy that does not interact with study drug, and no HIV/AIDS-associated opportunistic infection in the last 12 months.
* Use of any potent CYP3A4 inhibitors or inducers or moderate CYP3A4 inducers within 14 days or 5 half-lives (whichever is longer) before the first dose of study treatment. Note: Moderate CYP3A4 inhibitors are not prohibited
* Known hypersensitivity or severe reaction to pemigatinib, gemcitabine, cisplatin, or their excipients.
* Inadequate recovery from toxicity and/or complications from a major surgery before starting therapy.

Primary outcomes:
measure: Progression-free survival
timeFrame: Up to approximately 12 months
Secondary outcomes:
measure: Overall response rate
timeFrame: Up to approximately 12 months
measure: Overall survival
timeFrame: Up to approximately 12 months
measure: Duration of response
timeFrame: Up to approximately 12 months
measure: Disease control rate
timeFrame: Up to approximately 12 months
measure: Number of treatment-emergent adverse events
timeFrame: Up to approximately 12 months
measure: Quality of Life impact as assessed by the EQ-5D-3L questionnaire
timeFrame: Up to 12 months
measure: Quality of Life impact as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire
timeFrame: Up to 12 months
measure: Quality of Life impact as assessed by the EORTC QLQ-BIL21 questionnaire
timeFrame: Up to 12 months
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Mayo Clinic Arizona
state: Arizona
city: Greenbrae
country: United States
facility: Marin Cancer Care
state: California
city: Orange
country: United States
facility: UC Irvine Medical Center
state: California
city: Washington
country: United States
facility: Georgetown University-Lombardi Comprehensive Cancer Center
state: District of Columbia
city: Jacksonville
country: United States
facility: Mayo Clinic-Florida
state: Florida
city: Miami Beach
country: United States
facility: Mount Sinai Medical Center Comprehensive Cancer Center
state: Florida
city: Atlanta
country: United States
facility: Winship Cancer Institute of Emory University
state: Georgia
city: Chicago
country: United States
facility: University of Chicago Medical Center
state: Illinois
city: Fort Wayne
country: United States
facility: Parkview Research Center
state: Indiana
city: Iowa City
country: United States
facility: University of Iowa Hospital and Clinics
state: Iowa
city: Westwood
country: United States
facility: The University of Kansas Cancer Center
state: Kansas
city: New Orleans
country: United States
facility: Ochsner Clinic Foundation Ocf Ochsner Cancer Institute Oci
state: Louisiana
city: Baltimore
country: United States
facility: Johns Hopkins Oncology Center
state: Maryland
city: Boston
country: United States
facility: Boston Medical Center
state: Massachusetts
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center
state: Massachusetts
city: Detroit
country: United States
facility: Barbara Ann Karmanos Cancer Hospital
state: Michigan
city: Detroit
country: United States
facility: Henry Ford Hospital
state: Michigan
city: Farmington Hills
country: United States
facility: Karmanos Cancer Institute
state: Michigan
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Las Vegas
country: United States
facility: Comprehensive Cancer Centers of Nevada-Twain
state: Nevada
city: Florham Park
country: United States
facility: Summit Medical Group
state: New Jersey
city: New York
country: United States
facility: Icahn School of Medicine At Mount Sinai
state: New York
city: White Plains
country: United States
facility: White Plains Hospital
state: New York
city: Cleveland
country: United States
facility: University Hospitals Cleveland Medical Center
state: Ohio
city: Cleveland
country: United States
facility: Cleveland Clinic Foundation
state: Ohio
city: Portland
country: United States
facility: Providence Portland Med. Ctr
state: Oregon
city: Portland
country: United States
facility: Oregon Health & Science University
state: Oregon
city: Philadelphia
country: United States
facility: Fox Chase Cancer Center
state: Pennsylvania
city: Greenville
country: United States
facility: Greenville Hospital System University Medical Center Institute For Translational Oncology Research
state: South Carolina
city: Dallas
country: United States
facility: Baylor Scott and White Research Institute
state: Texas
city: Houston
country: United States
facility: Houston Methodist Research Institute
state: Texas
city: Newport News
country: United States
facility: Riverside Regional Medical Center
state: Virginia
city: Richmond
country: United States
facility: Virginia Commonwealth University
state: Virginia
city: Seattle
country: United States
facility: Virginia Mason Medical Center
state: Washington
city: Morgantown
country: United States
facility: West Virginia University Cancer Institute
state: West Virginia
city: Wauwatosa
country: United States
facility: Aurora Research Institute
state: Wisconsin
city: Graz
country: Austria
facility: Landeskrankenhaus Universitatsklinikum Graz
city: Innsbruck
country: Austria
facility: Innsbruck University Hospital
city: Linz
country: Austria
facility: Ordensklinikum Krankenhaus Der Barmherzigen Schwestern Linz
city: Salzburg
country: Austria
facility: Salzburger Universitatsklinikum
city: Steyr
country: Austria
facility: Landeskrankenhaus Steyr
city: Vienna
country: Austria
facility: Allgemeines Krankenhaus Der Stadt Wien
city: Bruxelles
country: Belgium
facility: Ulb Hospital Erasme
city: Bruxelles
country: Belgium
facility: Universitair Ziekenhuis Brussel
city: Gent
country: Belgium
facility: Universitair Ziekenhuis Gent
city: Haine-st-paul
country: Belgium
facility: Hospital de Jolimont
city: Kortrijk
country: Belgium
facility: Az Groeninge Campus Kennedylaan
city: Leuven
country: Belgium
facility: Universitaire Ziekenhuis Leuven - Gasthuisberg
city: Yvoir
country: Belgium
facility: Chu Ucl Namur University Hospital Mont-Godinne
city: Calgary
country: Canada
facility: Tom Baker Cancer Centre
state: Alberta
city: Winnipeg
country: Canada
facility: Cancercare Manitoba
state: Manitoba
city: Halifax
country: Canada
facility: Nova Scotia Health Authority/Qeii Health Sciences Centre
state: Nova Scotia
city: Toronto
country: Canada
facility: Princess Margaret Cancer Center
state: Ontario
city: Montreal
country: Canada
facility: McGill University Health Centre Research Institute
state: Quebec
city: Beijing
country: China
facility: Peking Union Medical College Hospital
city: Chengdu
country: China
facility: West China Hospital Sichuan University
city: Fuzhou
country: China
facility: Fujian Cancer Hospital
city: Guangdong
country: China
facility: Sun Yat-Sen Memorial Hospital Sun Yat-Sen University
city: Guangzhou
country: China
facility: Sun Yat-Sen Memorial Hospital Sun Yat-Sen University
city: Hangzhou
country: China
facility: Shulan Hangzhou Hospital Co Ltd
city: Hangzhou
country: China
facility: The Second Affiliated Hospital of Zhejiang University School of Medicine
city: Harbin
country: China
facility: Heilongjiang Province Cancer Hospital
city: Hefei
country: China
facility: University of Science and Technology of China-First Affiliated Hospital (Anhui Provincial Hospital)
city: Kunming
country: China
facility: Kunming 1St People'S Hospital
city: Nanjing
country: China
facility: Jiangsu Province Hospital
city: Shandong
country: China
facility: The Affiliated Hospital of Qingdao University
city: Shanghai
country: China
facility: Zhongshan Hospital Fudan University
city: Shanghai
country: China
facility: Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
city: SHanghai
country: China
facility: Xinhua Hospital
city: Sichuan
country: China
facility: Sichuan Cancer Hospital
city: Tianjin
country: China
facility: Tianjin Medical University Cancer Institute Hospital
city: Wuhan
country: China
facility: Tongji Hospital Huazhong University of Science and Technology
city: Wuhan
country: China
facility: Hubei Cancer Hospital
city: Yangzhou
country: China
facility: Northern Jiangsu Peoples Hospital
city: Herlev
country: Denmark
facility: Herlev Og Gentofte Hospital
city: Helsinki
country: Finland
facility: Docrates Cancer Center
city: Helsinki
country: Finland
facility: Helsinki University Central Hospital
city: Tampere
country: Finland
facility: Tampere University Hospital
city: Avignon Cedex 9
country: France
facility: Institut Sainte Catherine
city: Besançon
country: France
facility: Chu Besancon Hospital Jean Minjoz
city: Bordeaux Cedex
country: France
facility: Institut Bergonie
city: Clichy
country: France
facility: Hopital Beaujon
city: Limoges Cedex
country: France
facility: Chu de Limoges - Hospital Dupuytren
city: Lyon Cedex 08
country: France
facility: Hopital Prive Jean Mermoz
city: Marseille Cedex 5
country: France
facility: Chu Hopital de La Timone
city: Nantes
country: France
facility: Centre Hospitalier Universitaire de Nantes
city: Nice Cedex 02
country: France
facility: Centre Antoine Laccassagne
city: Paris Cedex 13
country: France
facility: Hospital Universitaire Pitie-Salpetriere
city: Paris Cedex 15
country: France
facility: Hopital Europeen Georges Pompidou (Hegp)
city: Pessac Cedex
country: France
facility: Centre Hospitalier Universitaire de Bordeaux - Hospital Haut-Leveque
city: Poitiers Cedex
country: France
facility: Hospital de La Miletrie
city: Rouen Cedex
country: France
facility: Hopital Charles Nicolle Chu Rouen Hospital de Bois-Guillaume
city: Saint Etienne
country: France
facility: University Hospital of Saint Etienne
city: Saint Herblain
country: France
facility: Centre de Lutte Contre Le Cancer - Institut de Cancerologie de L'Ouest - Rene Gauducheau
city: Toulouse Cedex 9
country: France
facility: Chu Toulouse Hopital Rangueil
city: Vandoeuvre Les Nancy
country: France
facility: Chu Vandoeuvre-Les-Nancy Hopital Brabois
city: Villejuif Cedex
country: France
facility: Institut Gustave Roussy
city: Aachen
country: Germany
facility: University Medical Center Rwth Aachen
city: Berlin
country: Germany
facility: Charite - Campus Virchow-Klinikum
city: Berlin
country: Germany
facility: Charite Universitaetsmedizin Berlin - Campus Charite Mitte
city: Bonn
country: Germany
facility: Universitatsklinikum Bonn Aoer
city: Bremen
country: Germany
facility: Klinikum Bremen-Nord
city: Dresden
country: Germany
facility: University Clinic Carl Gustav Carus Technical University Dresden
city: Frankfurt Am Main
country: Germany
facility: Klinikum Der Johann Wolfgang Goethe University
city: Freiburg
country: Germany
facility: University Medical Center Freiburg
city: Hamburg
country: Germany
facility: Universitatsklinikum Hamburg Eppendorf
city: Hamburg
country: Germany
facility: Asklepios Klinik Altona
city: Hannover
country: Germany
facility: Hannover Medical School
city: Homburg / Saar
country: Germany
facility: Universitaetsklinikum Des Saarlandes
city: Koln
country: Germany
facility: Universitatsklinikum Koln
city: Leipzig
country: Germany
facility: Universitatsklinikum Leipzig Aor
city: Ludwigsburg
country: Germany
facility: Klinikum Ludwigsburg
city: Magdeburg
country: Germany
facility: Otto-Von-Guericke-Universitat Magdeburg
city: Mainz
country: Germany
facility: Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
city: Munich
country: Germany
facility: University Hospital Grosshadern Munich
city: Nuernberg
country: Germany
facility: Klinikum Nuernberg
city: Tubingen
country: Germany
facility: Universitaetsklinikum in Tubingen
city: Tubingen
country: Germany
facility: University Hospital Tuebingen
city: ULM
country: Germany
facility: Universitatkinikums Ulm
city: Dublin 4
country: Ireland
facility: St. Vincent'S University Hospital
city: Beer-sheva
country: Israel
facility: Soroka University Medical Center
city: Haifa
country: Israel
facility: Rambam Health Care Campus
city: Jerusalem
country: Israel
facility: Hadassah University Hospital
city: Petach Tikva
country: Israel
facility: Rabin Medical Center - Beilinson Hospital
city: Tel Aviv
country: Israel
facility: Tel Aviv Sourasky Medical Center
city: Ancona
country: Italy
facility: Azienda Ospedaliero Universitaria Delle Marche
city: Bari
country: Italy
facility: Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari
city: Bergamo
country: Italy
facility: Ospedale Papa Giovanni Xxiii
city: Bologna
country: Italy
facility: Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
city: Candiolo
country: Italy
facility: Fondazione Del Piemonte Per L'Oncologia Ircc Candiolo
city: Catania
country: Italy
facility: Presidio Ospedaliero Garibaldi Nesima
city: Faenza
country: Italy
facility: Ospedale Degli Infermi - Faenza
city: Genova
country: Italy
facility: Irccs Azienda Ospedaliera Universitaria San Martino
city: Milano
country: Italy
facility: Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano
city: Milan
country: Italy
facility: Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele
city: Milan
country: Italy
facility: European Institute of Oncology
city: Milan
country: Italy
facility: Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
city: Modena
country: Italy
facility: A.O.U. Di Modena - Policlinico
city: Napoli
country: Italy
facility: Istituto Nazionale Tumori Irccs Fondazione Pascale
city: Napoli
country: Italy
facility: Universita Degli Studi Della Campania Luigi Vanvitelli U.O.C. Oncologia Medica
city: Orbassano
country: Italy
facility: Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano
city: Padova
country: Italy
facility: Iov - Istituto Oncologico Veneto Irccs
city: Pescara
country: Italy
facility: Presidio Ospedaliero Pescara
city: Pisa
country: Italy
facility: Azienda Ospedaliera Universitaria Pisana
city: Roma
country: Italy
facility: Fondazione Policlinico Universitario Agostino Gemelli Irccs
city: Roma
country: Italy
facility: Istituto Nazionale Tumori Regina Elena Irccs
city: Rome
country: Italy
facility: Universita Campus Bio Medico Di Roma
city: Rome
country: Italy
facility: Azienda Ospedaliera San Camillo Forlanini
city: Rozzano
country: Italy
facility: Irccs Istituto Clinico Humanitas
city: Siena
country: Italy
facility: Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria Alle Scotte
city: Verona
country: Italy
facility: Centro Ricerche Cliniche Di Verona (Crc)
city: Vicenza
country: Italy
facility: San Bartolo Hospital
city: Bunkyo
country: Japan
facility: University of Tokyo Hospital
city: Chiba-shi
country: Japan
facility: Chiba Cancer Center
city: Chiba
country: Japan
facility: Chiba University Hospital
city: Fukuoka-shi
country: Japan
facility: Kyushu University Hospital
city: Fukuoka
country: Japan
facility: National Hospital Organization Kyushu Cancer Center
city: Hiroshima-shi
country: Japan
facility: Hiroshima University Hospital
city: Hyogo
country: Japan
facility: Hyogo College of Medicine Hospital
city: Ishikawa
country: Japan
facility: Kanazawa University Hospital
city: Itabashi-ku
country: Japan
facility: Teikyo University Hospital
city: Kobe-shi
country: Japan
facility: Kobe University Hospital
city: Koto-ku
country: Japan
facility: Cancer Institute Hospital of Jfcr
city: Kyoto-shi
country: Japan
facility: Kyoto University Hospital
city: Matsuyama-shi
country: Japan
facility: Nho Shikoku Cancer Center
city: Mitaka-shi
country: Japan
facility: Kyorin University Hospital
city: Nagoya-shi
country: Japan
facility: Aichi Cancer Center Hospital
city: Niigata
country: Japan
facility: Niigata Cancer Center Hospital
city: Osaka-shi
country: Japan
facility: Osaka International Cancer Institute
city: Osakasayama City
country: Japan
facility: Kindai University Hospital
city: Saitama
country: Japan
facility: Saitama Cancer Center
city: Sapporo-shi
country: Japan
facility: Hokkaido University Hospital
city: Sendai-shi
country: Japan
facility: Tohoku University Hospital
city: Shimotsuke-shi
country: Japan
facility: Jichi Medical University Hospital
city: Shinjuku-ku
country: Japan
facility: Keio University Hospital
city: Shizuoka
country: Japan
facility: Shizuoka Cancer Center
city: Suita-shi
country: Japan
facility: Osaka University Hospital
city: Toyama-shi
country: Japan
facility: Toyama University Hospital
city: UBE
country: Japan
facility: Yamaguchi University Hospital
city: Wakayama
country: Japan
facility: Wakayama Medical University Hospital
city: Yokohama-shi
country: Japan
facility: Yokohama City University Medical Center
city: Yokohama-shi
country: Japan
facility: Kanagawa Cancer Center
city: Yufu-shi
country: Japan
facility: Oita University Hospital
city: Amsterdam
country: Netherlands
facility: Amsterdam University Medical Centre
city: Maastricht
country: Netherlands
facility: Maastricht Umc+
city: Rotterdam
country: Netherlands
facility: Erasmus Medical Center
city: Utrecht
country: Netherlands
facility: Umc Utrecht
city: Oslo
country: Norway
facility: Oslo University Hospital
city: Barcelona
country: Spain
facility: Hospital de La Santa Creu I Sant Pau
city: Barcelona
country: Spain
facility: Hospital General Universitario Vall D Hebron
city: Barcelona
country: Spain
facility: Hospital Clinic Barcelona Main
city: Cordoba
country: Spain
facility: Hospital Universitario Reina Sofia
city: Córdoba
country: Spain
facility: Hospital Universitario Reina Sofia
city: La Coruña
country: Spain
facility: Hospital Materno Teresa Herrera
city: Madrid
country: Spain
facility: Hospital General Universitario Gregorio Maranon
city: Madrid
country: Spain
facility: Hospital Universitario Ramon Y Cajal
city: Madrid
country: Spain
facility: Hospital Universitario Hm Sanchinarro
city: Málaga
country: Spain
facility: Hospital Regional Universitario de Malaga
city: Pamplona
country: Spain
facility: Clinica Universidad de Navarra (Cun)
city: Sabadell
country: Spain
facility: Hospital Universitari Parc Tauli
city: San Sebastian
country: Spain
facility: HOSPITAL UNiVERSITARIO DONOSTIA
city: Santander
country: Spain
facility: Hospital Universitario Marques de Valdecilla
city: Valencia
country: Spain
facility: Hospital General Universitario de Valencia
city: Solna
country: Sweden
facility: Karolinska Institute Universitetssjukhuset Solna
city: Bern
country: Switzerland
facility: Inselspital - Universitaetsspital Bern
city: Zuerich
country: Switzerland
facility: Universitatsspital Zurich
city: Aberdeen
country: United Kingdom
facility: Aberdeen Royal Infirmary
city: Cambridge
country: United Kingdom
facility: Addenbrookes Hospital
city: Cardiff
country: United Kingdom
facility: Velindre Cancer Centre
city: Coventry
country: United Kingdom
facility: University Hospital Coventry and Warwickshire
city: London
country: United Kingdom
facility: The Royal Marsden Nhs Foundation Trust - Chelsea
city: London
country: United Kingdom
facility: Imperial College Healthcare Nhs Trust - Hammersmith Hospital
city: London
country: United Kingdom
facility: University College London Hospitals (Uclh)
city: Maidstone
country: United Kingdom
facility: Kent Oncology Centre - Maidstone Hospital
city: Manchester
country: United Kingdom
facility: The Christie Nhs Foundation Trust
city: Sutton
country: United Kingdom
facility: The Royal Marsden Nhs Foundation Trust - Sutton
Study officials:
affiliation: Incyte Corporation
name: Peter Langmuir, MD
role: STUDY_DIRECTOR
References:
citation: Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, Melisi D, Macarulla T, Bridgewater J, Wasan H, Borad MJ, Abou-Alfa GK, Jiang P, Lihou CF, Zhen H, Asatiani E, Feliz L, Vogel A. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol. 2020 Oct;16(30):2385-2399. doi: 10.2217/fon-2020-0429. Epub 2020 Jul 17.